<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423384</url>
  </required_header>
  <id_info>
    <org_study_id>SMR-1471</org_study_id>
    <secondary_id>EUDRACT no.: 2006-003884-30</secondary_id>
    <nct_id>NCT00423384</nct_id>
  </id_info>
  <brief_title>Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation.</brief_title>
  <official_title>Ibandronate Versus Placebo as add-on to Active Vitamin D and Calcium in the Prevention of Bone Loss After Renal Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smerud Medical Research International AS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Smerud Medical Research International AS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Loss of bone mass is a common complication in patients with end-stage-renal failure, both&#xD;
      before and particularly after transplantation. In addition to standard underlying therapy&#xD;
      with calcium and active vitamin D, we will study the effect of ibandronate (a bisphosphonate)&#xD;
      versus placebo on bone mineral density as well as incidence of fracture rates after kidney&#xD;
      transplantation.We also wish to study whether any prevented bone loss will also lead to&#xD;
      reduced cardiovascular disease. Patients will be followed for 12 months after&#xD;
      transplantation, and the ibandronate treatment is one injection every 3 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Demographic, medical history, previous and current medication, as well as baseline&#xD;
      measurements of Bone Mineral Density (BMD), laboratory efficacy and safety variables as well&#xD;
      as Quality-of-Life scores will be undertaken in the period from 1 week prior to&#xD;
      transplantation until 1 week after transplantation. In this period, any existing fractures&#xD;
      will be determined using traditional x-ray of the thoraco-lumbar columna. Renal graft&#xD;
      functioning as well as transplantation complications will be followed tightly, and calcium&#xD;
      supplementation as well as active vitamin D (calcitriol) will be administered together with&#xD;
      the standard immunosuppressive regimen.&#xD;
&#xD;
      As soon as patients have recovered from transplantation, and renal functioning is considered&#xD;
      sufficiently stable, and no later than 28 days after the transplantation, qualified patients&#xD;
      will be randomised to receive either ibandronate or placebo, stratified by gender. Bone&#xD;
      mineral density and most of the clinical data and laboratory tests will then be followed&#xD;
      until 12 months after transplantation as described in the attached flowchart (section 11.1),&#xD;
      with hospital visits for administration of study drugs and follow-up of at 13, 26, 39 and 52&#xD;
      weeks after transplantation. Furthermore, all the patients will be followed prospectively&#xD;
      from the time of transplantation and for ten years with regard to cardiovascular events. Data&#xD;
      concerning cardiovascular events will be collected from the Norwegian renal registry for the&#xD;
      whole study population in the follow up period of about 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in percent lumbar BMD change from baseline to 12 months between the two treatment groups.</measure>
    <time_frame>December 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lumbar BMD change; absolute and relative</measure>
    <time_frame>December 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip BMD change; absolute and relative</measure>
    <time_frame>December 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radial BMD change; absolute and relative</measure>
    <time_frame>December 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Femural BMD change; absolute and relative</measure>
    <time_frame>December 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in height</measure>
    <time_frame>December 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in biochemical efficacy and bone markers</measure>
    <time_frame>December 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HRQoL scores (SF-36 and mini OQOL)</measure>
    <time_frame>December 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-transplant complications</measure>
    <time_frame>December 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of clinically significant safety laboratory variables</measure>
    <time_frame>December 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rates</measure>
    <time_frame>December 2010</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Renal Transplant</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibandronate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronate</intervention_name>
    <description>I.v.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Renal transplant recipients&#xD;
&#xD;
          -  Adults, â‰¥ 18 years of age&#xD;
&#xD;
          -  Either gender&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persisting s-Ca &gt; 2.55 mmol/L (through the first two weeks after transplantation)&#xD;
&#xD;
          -  Impaired graft functioning (estimated GFR &lt;30 ml/min)&#xD;
&#xD;
          -  Previous (within the last 12 months) treatment with bisphosphonates, sodium fluoride,&#xD;
             calcitonin, strontium, PTH, SERM, growth hormone or anabolic steroids at any time&#xD;
             before transplantation.&#xD;
&#xD;
          -  Known adynamic bone disease&#xD;
&#xD;
          -  Previous parathyroidectomy&#xD;
&#xD;
          -  Pregnant or lactating females or females of childbearing potential who do not use an&#xD;
             approved method of contraception (oral contraceptives or IUD); positive urine&#xD;
             pregnancy test, where applicable.&#xD;
&#xD;
          -  Use of any investigational drug (s) and/or device(s)&#xD;
&#xD;
          -  Previous participation in this trial&#xD;
&#xD;
          -  History of hypersensitivity to bisphosphonates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Knut T Smerud, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Smerud Medical Research International AS, Drammensveien 41, N-0271 Oslo, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rikshospitalet-Radiumhospitalet Medical Center</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>January 17, 2007</study_first_submitted>
  <study_first_submitted_qc>January 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <last_update_submitted>March 22, 2010</last_update_submitted>
  <last_update_submitted_qc>March 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Knut Smerud</name_title>
    <organization>Smerud Medical Research International AS</organization>
  </responsible_party>
  <keyword>Ibandronate</keyword>
  <keyword>Placebo</keyword>
  <keyword>Doubleblind</keyword>
  <keyword>Bone</keyword>
  <keyword>loss</keyword>
  <keyword>Kidney</keyword>
  <keyword>transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibandronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

